Impact Partnership Wealth LLC Purchases 483 Shares of Eli Lilly and Company $LLY

Posted by Geri Gentry on Jul 3rd, 2026

Eli Lilly and Company logo Impact Partnership Wealth LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 26.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,326 shares of the company’s stock after purchasing an additional 483 shares during the quarter. Impact Partnership Wealth LLC’s holdings in Eli Lilly and Company were worth $2,140,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of LLY. Spire Wealth Management increased its stake in Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after buying an additional 592 shares during the period. Coldstream Capital Management Inc. increased its position in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after acquiring an additional 8,659 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares during the period. Stonebridge Capital Advisors LLC grew its stake in Eli Lilly and Company by 318.1% in the third quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company’s stock worth $8,026,000 after purchasing an additional 8,003 shares in the last quarter. Finally, Iams Wealth Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $754,000. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Medicare’s inclusion of GLP-1 weight-loss drugs has sparked renewed optimism that Eli Lilly’s obesity portfolio could reach more patients and drive additional sales. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
Positive Sentiment: Several market notes remain constructive on LLY, citing leadership in GLP-1 therapies, a broadening pipeline, and diversified growth drivers as support for long-term upside despite a rich valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
Positive Sentiment: Analysts and commentators highlighted Lilly as a top healthcare name, with some arguing the stock still has double-digit upside if GLP-1 demand and new products continue to scale. Eli Lilly Price Prediction: The Case for Double-Digit Upside
Positive Sentiment: Lilly and Innovent reached a commercialization deal for Verzenios in China, which could expand access in oncology while preserving Lilly’s manufacturing role. Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
Positive Sentiment: TipRanks said AI could become a meaningful long-term growth tailwind for Eli Lilly by improving drug discovery and development efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
Neutral Sentiment: Lilly continued to receive favorable media coverage and mentions in broader pharma/medical stock screens, which may support investor attention but does not change fundamentals on its own.
Negative Sentiment: U.S. lawmakers opened a national security probe into Lilly’s clinical trial activities in China, asking for details on oversight and data access by a July 17 deadline. Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers
Negative Sentiment: China’s Hybio filed a patent challenge against Lilly’s tirzepatide, raising a potential intellectual-property risk for one of its most important weight-loss drugs. China’s Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug Tirzepatide

Eli Lilly and Company Stock Performance

LLY opened at $1,208.37 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,238.00. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.14 trillion, a P/E ratio of 42.93, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51. The firm’s 50-day moving average price is $1,059.70 and its 200-day moving average price is $1,026.87.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, June 22nd. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,235.07.

Check Out Our Latest Stock Analysis on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.